Cardiac hypertrophy determines digitalis action on intracellular Ca2+ in human myocardium

J R Lopez1, N Linares, P A Brady

  • 1Centro de Biofisica y Bioquimica, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela.

Insights

Ventricular hypertrophy increases intracellular calcium levels more significantly when treated with digitalis (strophanthidin). The degree of hypertrophy inversely impacts this calcium increase in human heart muscle.

Area of Science:

  • Cardiology
  • Biochemistry
  • Physiology

Background:

  • Ventricular hypertrophy alters ion transporters crucial for digitalis efficacy.
  • The effect of digitalis on intracellular cations in hypertrophied human myocardium is not well understood.

Purpose of the Study:

  • To investigate the impact of digitalis (strophanthidin) on intracellular calcium (Ca2+) levels in human myocardium with and without ventricular hypertrophy.
  • To determine how ventricular hypertrophy influences the response to digitalis treatment.

Main Methods:

  • Utilized double-barreled Ca2+-selective microelectrodes to measure Ca2+ activity and membrane potential.
  • Analyzed myocardial samples from patients with and without ventricular hypertrophy before and after strophanthidin exposure.

Main Results:

  • Ventricular hypertrophy led to a greater increase in diastolic Ca2+ levels upon strophanthidin exposure compared to non-hypertrophied samples.
  • The increase in Ca2+ induced by strophanthidin was inversely proportional to the myocardial mass in hypertrophied hearts.

Conclusions:

  • The extent of ventricular hypertrophy dictates the digitalis-induced changes in intracellular Ca2+ within the human myocardium.
  • Findings highlight the importance of considering myocardial hypertrophy when assessing digitalis treatment outcomes.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...